SAI Life Sciences Ltd.
1,396.00
INR
+1.50
(+0.11%)
ISIN
INE570L01029
Return %
Stock
S&P 500
1Y
58.71
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Krishnam Raju Kanumuri
- Full Time Employees
- 5,227
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- L4- 01 & 02, SLN Terminus Survey Hyderabad TG India 500032
- IPO Date
- Dec 18, 2024
- Website
- sailife.com
- Similar Companies
- Business
- Sai Life Sciences Ltd is an India-based contract research, development, and manufacturing organization (CRDMO) serving global pharmaceutical and biotechnology companies. It offers comprehensive integrated services and products across drug discovery, development, and commercial manufacturing of small molecule active pharmaceutical ingredients (APIs) and intermediates. The company specializes in medicinal chemistry, custom synthesis, process development and optimization, analytical and bioanalytical services, drug metabolism and pharmacokinetics (DMPK), toxicology, and commercial API manufacturing. Its product portfolio includes advanced intermediates, innovative APIs, and veterinary APIs, with core therapeutic areas such as oncology, central nervous system, inflammation, antivirals, and vitamin D derivatives. Sai Life Sciences operates manufacturing and R&D facilities primarily in India, with its headquarters in Hyderabad, and serves 17 of the top 20 global pharmaceutical companies. Founded in 2003, Sai Life Sciences has recently expanded significantly with new strategic developments including the inauguration of a dedicated veterinary API manufacturing facility in Bidar and completion of Phase II expansion of its flagship API manufacturing unit, increasing capacity to 700 KL. It is set to double its process R&D capacity with a new center at its Hyderabad campus, targeting completion in 2026. The company announced an integrated CMC (Chemistry, Manufacturing, and Controls) partnership with Agility Life Sciences and Centrix Pharma Solutions to provide comprehensive drug development services. Sai Life Sciences completed its initial public offering in late 2024, raising $366 million, and has reported strong financial growth with a 36% revenue increase and 100% net profit growth in recent quarters. It has an SBTi-validated climate action plan and continues to deepen partnerships with new biopharma clients worldwide to support the launch of innovative medicines globally. The company targets innovator pharmaceutical and biotech companies across North America, Europe, Japan, and India as its key markets.
Company News
サイ・ライフ・サイエンシズが2024～2025年度サステナビリティレポートを発表
Sai Life Sciences Releases Sustainability Report 2024–25